EWEdwards Lifesciences Corporation

EW Stock Price, Valuation & Chart | Edwards Lifesciences Corporation

Compare

$90.820+0.08 (+0.09%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Medical - Devices EW intrinsic value EW calculated fair value vs price

Overview Financials Dividends Ratios

EW Historical price chart

EW Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization52.29B

PE Ratio33.64

EPS2.7

Trading Volume2.60M

Today's High/Low92.36/90.55

Dividend Yield0.00

52 Week High/Low96.29/72.3

Shares Outstanding575.80M

EW Financial Statement

EW Analyst ratings

EW Analysis & performance metrics

EW Company profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe,…

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral…

EW Management team

Name

Position

Andrew M. Dahl

Principal Accounting Officer, Senior Vice President & Corporate Controller

Dirksen J. Lehman

Corporate Vice President of Public Affairs

Donald E. Bobo Jr.

Corporate Vice President of Strategy & Corporate Development

Daveen Chopra

Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies

Todd J. Brinton FACC, M.D.

Corporate Vice President of Advanced Technology & Chief Scientific Officer

Mark Wilterding

Vice President of Investor Relations

Mark D. Peterson

Corporate Vice President & General Counsel

Jean-Luc Lemercier

Corporate Vice President of Japan, Asia Pacific & Greater China

Name

Position

Andrew M. Dahl

Principal Accounting Officer, Senior Vice President & Corporate Controller

Dirksen J. Lehman

Corporate Vice President of Public Affairs

Donald E. Bobo Jr.

Corporate Vice President of Strategy & Corporate Development

Daveen Chopra

Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies

Todd J. Brinton FACC, M.D.

Corporate Vice President of Advanced Technology & Chief Scientific Officer

Mark Wilterding

Vice President of Investor Relations

Mark D. Peterson

Corporate Vice President & General Counsel

Jean-Luc Lemercier

Corporate Vice President of Japan, Asia Pacific & Greater China

Management Team

Andrew M. Dahl

Principal Accounting Officer, Senior Vice President & Corporate Controller

Dirksen J. Lehman

Corporate Vice President of Public Affairs

Donald E. Bobo Jr.

Corporate Vice President of Strategy & Corporate Development

Daveen Chopra

Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies

Todd J. Brinton FACC, M.D.

Corporate Vice President of Advanced Technology & Chief Scientific Officer

Mark Wilterding

Vice President of Investor Relations

Mark D. Peterson

Corporate Vice President & General Counsel

Jean-Luc Lemercier

Corporate Vice President of Japan, Asia Pacific & Greater China

Management

Andrew M. Dahl

Principal Accounting Officer, Senior Vice President & Corporate Controller

Dirksen J. Lehman

Corporate Vice President of Public Affairs

Donald E. Bobo Jr.

Corporate Vice President of Strategy & Corporate Development

Daveen Chopra

Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies

Todd J. Brinton FACC, M.D.

Corporate Vice President of Advanced Technology & Chief Scientific Officer

Mark Wilterding

Vice President of Investor Relations

Mark D. Peterson

Corporate Vice President & General Counsel

Jean-Luc Lemercier

Corporate Vice President of Japan, Asia Pacific & Greater China

Total 8 executives

EW Frequently asked questions

What is Edwards Lifesciences Corporation (EW) Stock Price?

Current stock price of Edwards Lifesciences Corporation (EW) stock is $90.820. The stock price is +0.09% higher in the session. The intraday range can be seen from this page. Volume of Edwards Lifesciences Corporation (EW) stock is 2.60M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Edwards Lifesciences Corporation (EW) stock price going up or down today?

The stock price of Edwards Lifesciences Corporation (EW) can change with earnings, company news, and overall market sentiment. Edwards Lifesciences Corporation operates in the Healthcare / Medical - Devices market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Edwards Lifesciences Corporation stock expensive at its current price?

Whether Edwards Lifesciences Corporation looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for EW on this page is 33.64. EPS on this page is 2.70. Compare those figures with peers and growth expectations before deciding if the current Edwards Lifesciences Corporation price is justified.

How has the stock price of Edwards Lifesciences Corporation (EW) performed historically?

Historical performance for Edwards Lifesciences Corporation (EW) is shown on the price chart on this page. Review multi-period moves alongside volume to see how EW reacted to past earnings and market events.

Should I buy Edwards Lifesciences Corporation (EW) stock, at this price?

Buying Edwards Lifesciences Corporation (EW) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.